| Wolf, Dominik |
| Recruiting | 3 | 70 | Europe | Luspatercept, Reblozyl | GWT-TUD GmbH, Celgene | Myelodysplastic Syndromes | 12/24 | 06/25 | | |
CLL17, NCT04608318 / 2019-003854-99: Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL) |
|
|
| Active, not recruiting | 3 | 897 | Europe, RoW | Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro | German CLL Study Group, Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG), Janssen Pharmaceutica N.V., Belgium, AbbVie, Hoffmann-La Roche | Chronic Lymphoid Leukemia | 09/27 | 09/27 | | |
DASTOP2, NCT03573596: Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment |
|
|
| Recruiting | 2 | 134 | Europe | Dasatinib | Amsterdam UMC, location VUmc, Uppsala University Hospital, Skane University Hospital, Helsinki University Central Hospital, Odense University Hospital, Henri Mondor University Hospital, St. Olavs Hospital, Helse Stavanger HF, Aarhus University Hospital, University Hospital, Bonn | CML, Relapsed | 02/23 | 02/24 | | |
CLL-Frail, NCT04883749: Efficacy of Acalabrutinib in Very Old or Frail Patients with Treatment-naïve or Relapsed/Refractory CLL |
|
|
| Active, not recruiting | 2 | 53 | Europe | Acalabrutinib, Calquence, ACP-196 | German CLL Study Group | Chronic Lymphoid Leukemia | 05/25 | 05/25 | | |
| Active, not recruiting | 2 | 168 | Europe, RoW | MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab | Miltenyi Biomedicine GmbH, ICON plc | Diffuse Large B-cell Lymphoma | 12/24 | 07/29 | | |
| Recruiting | 1 | 12 | Europe | APN401 | invIOs GmbH | Advanced Solid Tumor | 03/24 | 03/24 | | |
NCT06250465: AGMT Austrian CLL (Chronic Lymphocytic Leukemia) Registry |
|
|
| Recruiting | N/A | 500 | Europe | | Arbeitsgemeinschaft medikamentoese Tumortherapie | Chronic Lymphocytic Leukemia | 12/27 | 12/27 | | |
| Recruiting | N/A | 130 | Europe | Next Generation Sequencing, Tumorimmunological examinations - multiplex assays/quantitative polymerase chain reaction, flow cytometry, Metagenomics of stool samples, Clinical/demographic data, Elicitation of the HRQoL | Medical University Innsbruck, University Hospital, Bonn, Universitätsklinikum Leipzig | Myelodysplastic Syndromes | 01/23 | 01/23 | | |
| Recruiting | N/A | 60 | Europe | | University of Leipzig, Deutsche Krebshilfe e.V., Bonn (Germany) | MDS, MDS/MPN | 03/25 | 03/25 | | |
| Teichmann, Lino |
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy |
|
|
| Active, not recruiting | 3 | 777 | Europe, RoW | Gilteritinib, ASP2215, Midostaurin, Rydapt | Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc. | Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 | 10/25 | 06/33 | | |
NCT04628026: Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 |
|
|
| Recruiting | 3 | 650 | Europe | Venetoclax, Placebo, Standard chemotherapy, Autologous stem cell transplantation, Allogeneic stem cell transplantation | University of Ulm, Stichting Hemato-Oncologie voor Volwassenen Nederland | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 02/25 | 02/31 | | |
NCT06652438: Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML |
|
|
| Not yet recruiting | 3 | 415 | Europe | Revumenib, Placebo | Stichting Hemato-Oncologie voor Volwassenen Nederland, German-Austrian Acute Myeloid Leukemia Study Group, United Kingdom AML Research Network | Acute Myeloid Leukemia, Adult | 05/28 | 05/31 | | |
NCT05237713: Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients |
|
|
| Terminated | 2 | 10 | Europe | Canakinumab Injection, Ilaris(R) | University of Leipzig, Novartis Pharmaceuticals | Anemia, Myelodysplastic Syndromes | 02/24 | 02/24 | | |
AMLSG BiO, NCT01252485: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - the Biology and Outcome (BiO)-Project |
|
|
| Recruiting | N/A | 50000 | Europe | | University of Ulm | Acute Myeloid Leukemia (AML), MDS/AML | 12/44 | 12/44 | | |
